iBio (IBIO) Non-Current Debt (2020 - 2025)
iBio (IBIO) posted quarterly Non-Current Debt of $64000.0 for Q2 2025, down 91.64% year-over-year from $766000.0 in Q2 2024, and down 90.05% quarter-over-quarter from $643000.0 in Q4 2024.
iBio (IBIO) Non-Current Debt (2020 - 2025) Analysis & Trends
iBio (IBIO) has reported Non-Current Debt for 6 consecutive years, with $64000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Non-Current Debt fell 91.64% year-over-year to $64000.0; the TTM figure through Jun 2025 stood at $64000.0 (down 91.64% YoY), while the FY2025 annual figure was $64000.0, down 91.64% from the prior year.
- Non-Current Debt declined to $64000.0 in Q2 2025 per IBIO's latest filing, from $643000.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $22.1 million in Q1 2022 and bottomed at $34000.0 in Q1 2021.
- Historically, Non-Current Debt has averaged $5.8 million across 5 years, with a median of $674500.0 in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Debt jumped 64958.82% — and 2025, when it tumbled 91.64%.
- iBio's Non-Current Debt stood at $22.1 million in 2021, then increased by 0.3% to $22.1 million in 2022, then plunged by 98.91% to $241000.0 in 2023, then jumped by 166.8% to $643000.0 in 2024, then tumbled by 90.05% to $64000.0 in 2025.
- Business Quant data shows IBIO's Non-Current Debt at $64000.0 in Q2 2025, $643000.0 in Q4 2024, and $706000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 64,000.00 |
| Dec 31, 2024 | 643,000.00 |
| Sep 30, 2024 | 706,000.00 |
| Jun 30, 2024 | 766,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Mar 31, 2022 | 22.12 Mn |
| Dec 31, 2021 | 22.05 Mn |
| Mar 31, 2021 | 34,000.00 |
| Dec 31, 2020 | 135,000.00 |
| Sep 30, 2020 | 238,000.00 |
| Jun 30, 2020 | 339,000.00 |